A clinical trial is currently being conducted in the United States to assess a medication that could potentially prolong the lifespan of dogs.

This research, referred to as the STAY trial, is organized by Loyal, an animal health firm based in San Francisco.

The double-blind, placebo-controlled study involves at least a thousand older dogs, with the aim of obtaining approval from the U.S. Food and Drug Administration (FDA) based on the results.

The trial is built on the success of earlier preclinical and pilot investigations.

According to Alex Robb, medical director at Goodheart Animal Health Center in Colorado, the dogs involved will receive daily doses of the medication for a four-year period, accompanied by regular clinical evaluations.

Researchers will assess whether the drug has a significant effect on longevity after the study concludes.

To be eligible for the trial, dogs must be at least ten years old and weigh a minimum of fourteen pounds.

Pet owners must agree to transfer their dog’s primary care to a clinic participating in the study and commit to several veterinary visits throughout the four years.

The first year entails six visits, followed by two visits each year in the following years.

The study aims to explore the factors that contribute to aging in dogs, such as their faster metabolic rate compared to humans.

While advancements in veterinary medicine have enhanced canine healthcare, dogs' overall lifespan has not kept pace with the increasing longevity seen in humans.

Loyal intends to leverage the data gathered to seek conditional FDA approval for the drug by the year's end.

Recruitment for the trial is still ongoing at various clinics nationwide.